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Abstract
Background: Many treatment options exist for the management of anterior epistaxis. However, little is known
about treatment outcomes. The objective was to identify the currently utilised methods of management and
outcomes for patients with anterior epistaxis presenting to the emergency department (ED) at a Canadian
tertiary care center.
Methods: A retrospective review of ED visits from January 2012-May 2014 for adult patients with a diagnosis
of anterior epistaxis was performed. Patient demographic data, comorbidities, and treatment methods were
documented. The effectiveness of different treatment modalities was determined.
Results: Three hundred fifty-three primary anterior epistaxis cases were included. Mean patient age was 70 years and
49 % of patients were female. Comorbidities included hypertension (56 %), diabetes (19 %), CAD (28 %), and
atrial fibrillation (27 %). A large proportion of the cohort (61 %) was on at least one anticoagulant or antiplatelet
therapy. The most common utilised treatment modalities were silver nitrate cauterization, Merocel®, petroleum gauze
packing, nasal clip and 15 % were simply observed. Initial treatment success was achieved in 74 % of cases. Of patients
receiving specific treatment modalities, silver nitrate cauterization had the highest success rate at 80 %. 26 % of
patients returned to the ED for recurrence of epistaxis with highest rates occurring in the nasal clip (59 %),
Merocel® (26 %), and petroleum gauze packing (42 %) groups.
Conclusions: The differences in recurrence rate among the different treatment modalities observed may be
due to true differences in effectiveness or differences in treatment selection by the ED physicians based on
severity of epistaxis. Cauterization with silver nitrate, however, offers the added benefit of no need for follow
up. Further study is needed to elucidate the most efficacious treatment modality based on epistaxis severity.
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Background
Epistaxis, is an exceedingly common presenting problem
to hospitals in North America accounting for approxi-
mately 1 in 200 emergency department (ED) visits in the
United States [1]. Although difficult to truly assess, it
has been estimated that 60 % of the population has at
least 1 episode of epistaxis in their lifetime of which 6 %
seek medical treatment [2]. The sheer incidence of
epistaxis constitutes it as an important condition in
terms of cost, time and resource management. Thus,
it is important to identify the most efficacious treat-
ment modality in the realms of treatment success.
There are many treatment modalities and algorithms
for epistaxis described in the literature [3–9]. Most ap-
proaches describe initiating packing and nasal pressure
and escalating to more invasive and time consuming
treatments if that fails. For anterior epistaxis there is evi-
dence for the use of chemical cautery [10], anterior
packing [5], and other hemostatic matrices [4]. All of
these modalities have been shown to have good efficacy
in achieving hemostasis. However, there is insufficient
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literature evaluating these modalities and their effective-
ness when utilised in the ED. Further, at this time there
are no widely accepted treatment guidelines and treat-
ment selection is a matter of individual ED physician
preference.
Importance
Considering that anterior epistaxis is a very common
and treatable condition it is important to optimize effi-
ciency and effectiveness when treating this disorder. Al-
though, there is evidence for each individual treatment
modality, the literature is deficient as to current ED
physician practices and the outcomes for use of the
many modalities.
Goals of this investigation
The purpose of this study was twofold, first to assess the
current practices utilised in a Canadian Tertiary Care
center for anterior epistaxis management and second, to
evaluate the outcomes of these treatments.
Methods
Study design and setting
With the approval of the Research Ethics Board at the
Ottawa Hospital Research Institute a retrospective re-
view of all patient visits to the ED at The Ottawa
Hospital (TOH), a Canadian tertiary care center, with
a primary diagnosis of anterior epistaxis during the
period of January 2012 to May 2014 was performed.
Selection of participants
Adult patients with a primary diagnosis of epistaxis in
the emergency department were included in this study.
Records were identified by the health records depart-
ment using the ICD-10 code for epistaxis (R04-0). The
epistaxis codes do not differentiate between anterior and
posterior epistaxis; thus all records were hand searched
and patients with a diagnosis of posterior epistaxis or
concurrent anterior and posterior epistaxis were ex-
cluded. Patients that presented with epistaxis due to a
complication of pre-existing conditions such as end
stage cancer were excluded. Patients who died during
the ED visit for reasons other than epistaxis were also
excluded. Patients with an initial visit to the ED for
packing removal that had been placed at a different in-
stitution and patients who were treated as posterior epi-
staxis despite having an anterior epistaxis diagnosis were
also excluded. Patients who received treatment with a
modality that was used in five or fewer cases were also
excluded from analysis. See Fig. 1 for study flow chart.
Methods and measurements
From the identified charts data was abstracted including
patient demographics, comorbidities, the treatment mo-
dalities used, course in the emergency department, ad-
mission, concurrent medical disorders, medications and
finally recurrence or ED follow-up information. Treat-
ment modalities identified for data abstraction included
conservative (no treatment), nasal clip, petroleum gauze
Fig. 1 Study flowchart
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packing, Merocel® packing, Floseal®, Surgicel®, Epistat®,
silver nitrate cautery, electrocautery, endoscopic surgery,
arterial embolization and other treatments not otherwise
specified (NOS). The “other packing” group in this study
received anterior petroleum gauze packing or equivalent.
Outcomes
For each treatment modality, success was defined as pa-
tients who were diagnosed with anterior epistaxis, who
received treatment and did not present with a recur-
rence within 14 days of their original date of presenta-
tion [11]. Conversely, failure was defined as the patients
who had an ipsilateral recurrence of epistaxis within
14 days of initial treatment. The treatment type was re-
corded based on the treatment modality used to arrest
the bleeding that led to the patient’s discharge from the
ED. Follow-up was defined as patients who were admin-
istered a specific treatment and who were subsequently
booked and received follow-up care in the ED for either
packing removal or to check the site of epistaxis or for
any other reason. For patients requiring an inpatient
admission, the length and reason for admission were
recorded.
Analysis
All statistical calculations were done using SAS (version
9.3). Categorical variables were summarized using fre-
quency counts and percentages, while continuous vari-
ables were summarized using the mean (SD) or median
(IQR), as appropriate. Where necessary, initial testing for
associations between categorical variables was done using
either chi-square or Fisher’s Exact tests. Modeling of cat-
egorical outcomes was done using logistic regression.
Results
Characteristics of study subjects
A total of 419 visits to the ED with a primary diagnosis
of epistaxis occurred from January 2012 to May 2014.
Sixty-six visits were excluded from this analysis, reasons
for exclusion are shown in Fig. 1. Overall, 353 anterior
epistaxis cases were included in this study; the demo-
graphics and comorbidities are summarized in Table 1.
The individuals included in this study had a mean age of
70 and 49 % were women. A large proportion (61 %) of
the patients were on some type of anticoagulant or anti-
platelet medication. Of the comorbidities recorded,
hypertension, diabetes, coronary artery disease, atrial fib-
rillation, did not have a statistically significant impact on
treatment failure (p > 0.05).
Main results
The outcome of each treatment is summarized in
Table 2. In all, the overall primary treatment failure rate
was 26 % (91 patients) and in total 26.6 % (94 patients)
returned to the ED for a scheduled follow-up after dis-
charge from the ED. Of the individuals requiring follow-
up, 89 (95 %) returned for packing removal (53 patients
had Merocel® packing), in 3 (3.1 %) patients packing was
left in situ at the follow up visit and 2 (2.1 %) patients
attended the follow up visit even though their packing
had fallen out on its own before their appointment. Of
the 94 patients requiring follow up, 22 (23 %) required
further intervention (10 patients with Merocel® packing)
for epistaxis at the time packing removal. There was no
difference in bleeding rates post pack removal between
the different types of packing.
When silver nitrate was compared to petroleum gauze
packing, those in silver nitrate group were less likely to
fail (OR 0.335, 95 % CI 0.160–0.703 p = 0.0038). When
silver nitrate was compared to Merocel® packing, the
odds of recurrence were lower with silver nitrate than
with Merocel® (OR 0.694, 95 % CI 0.364–1.322, p = 0.27),
however this was not statistically significant.
When evaluating potential risk factors for the devel-
opment of epistaxis, anticoagulation was identified
Table 1 Patient demographics
Characteristic Value










Other blood disorders 12 (3)





Table 2 Treatment outcomes for management of anterior
epistaxis
Treatment N (%) Failure N (%)
Silver nitrate 122 (35) 24 (20)
Merocel 92 (26) 24 (26)
No treatment 54 (15) 11 (20)
Other packinga 45 (13) 19 (42)
Otherb 23 (6) 3 (13)
Nasal clip 17 (5) 10 (59)
aOther packing included non-dissolvable anterior packs the majority being
Vaseline gauze packing
bOther included surgicel, decongestant with topical anesthetic alone
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from the patient characteristics, through logistical re-
gression. The type of anticoagulant or antiplatelet
medication individuals in the study were receiving is
summarized in Table 3. Given the large variety of
anticoagulation and antiplatelet medications, they
were grouped into 3 categories for analysis as seen in
Table 4. Overall, 61 % of the individuals were on at
least one antiplatelet or anticoagulant medication. Of
those not on any anticoagulant or antiplatelet agent,
the failure rate for anterior epistaxis treatment was
18 %. In contrast, for individuals on any anticoagu-
lant/antiplatelet agent the failure rate was 30 %.
There was a statistically significant association be-
tween the use of anticoagulant/antiplatelet medication
and the recurrence of epistaxis (p = 0.0119). 73 % of
all patients who failed treatment were on at least one
antiplatelet or anticoagulant medication.
Discussion
Overall there were 353 cases of anterior epistaxis ana-
lyzed in this study for outcomes of treatment received in
the ED. Silver nitrate cautery was the most popular mo-
dality used accounting for 35 % of initial treatment.
However, the treatment of anterior epistaxis proved to
be quite variable with Merocel®, petroleum gauze pack-
ing/other packing or a nasal clip commonly being used.
The group of patients who received no treatment at
the ED was not used as a control to compare other
treatment modalities given those patients not requir-
ing treatment had stopped bleeding when seen by the
ED physician or they did not have a bleeding episode
of such a severity that it required any treatment. It
would be an unfair comparison due to the inherent
clinical difference in epistaxis severity. When the sil-
ver nitrate group was compared to the petroleum
gauze packing, those in silver nitrate group were less
likely to fail (p = 0.0038).
In this cohort, silver nitrate treatment had the low-
est rate of treatment failure (20 %) of the most uti-
lised treatment modalities and it also had the added
benefit of not requiring an additional routine ED visit,
as non-dissolvable packing did. Selection bias may
have affected this observation as silver nitrate may
have been used by ED physicians only in less severe
cases. Other literature has described good success
rates for anterior dissolvable packing [3, 4, 11, 12]
and surgical techniques [3], however the number of
individuals receiving these treatments in our cohort
were too small for analysis.
Epistaxis management, as with any medical condi-
tion, should be tailored to the patient and the clinical
situation [8]. In this study most patients with anterior
epistaxis received successful management with silver
nitrate cautery or Merocel® packing being the most
commonly used modalities. Silver nitrate was particularly
advantageous as it showed promising results insofar as
treatment success without a need for follow-up. However,
in these cases the site of bleeding was identifiable on an-
terior rhinoscopy examination and amenable to cautery
with silver nitrate. This is in keeping with other studies
which have shown that when the source of bleeding in
epistaxis is identifiable chemical cautery has excellent suc-
cess in the treatment of anterior epistaxis [2, 8–10].
Exploring the reasons for treatment failure, the use of
blood thinners is largely believed to have an effect. In
our study it was found that being on any anticoagulant
or antiplatelet agent, including ASA, significantly in-
creased the odds of recurrence after discharge from the
ED (p = 0.0106). The rate of treatment failure in pa-
tients on any anticoagulant/antiplatelet agent was 30 %,
in ASA alone was 33 % and in another regimen was
29 %, these were significantly greater than the failure
rate of 18 % seen in the individuals not on any such
therapy (p < 0.0119).
As with any study, this study has some limitations.
The population size studied was not large enough to ac-
curately comment on less commonly used forms of
management for anterior epistaxis. Similarly, there was
no data or rating on the severity of epistaxis on arrival
to the ED that, in the end, may have affected physician
treatment selection and also affected recurrence. This
Table 3 Types of anticoagulation (AC)/antiplatelet (AP)
medications used by patient population
Medication N (%)








Other anticoagulant 7 (2)
Table 4 Outcomes of treatment success and failure based on
anticoagulation/antiplatelet use profile
Anticoagulant/Antiplatelet N Failure N (%)
None 136 25 (18)
Any anticoagulant/antiplatelet 217 66 (30)
ASA only 85 28 (33)
Other regimen 132 38 (29)
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may confound the relationship between the treatment
modality used and outcomes. At the institution of this
study, patients presenting acutely with anterior epistaxis
are seen first by an emergency physician, who may or
may not utilise nasal endoscopy if the bleeding site is
not readily identified on anterior rhinoscopy. Similarly, a
standardized approach to patient evaluation prior to
treatment selection was not utilised for the patients in
this series. A standard approach to patient evaluation for
anterior epistaxis such as the application of a topical de-
congestant/vasoconstrictor and analgesia prior to assess-
ment for a bleeding site is needed. Given that the
decision to use cautery requires visualization of the
bleeding site the choice between packing and cautery for
an ED physician may then have been affected. Further,
there may also have been patients who were lost to
follow up due to ED visits at other locations in the
case of re-bleeding. Despite the limitations in this
study, the large patient population allowed for in-
formative evaluation of the treatment data.
Conclusions
In summary, the current practices for the treatment of
anterior epistaxis in the ED are quite variable. There are
many modalities currently in use and there is not yet an
accepted evidence-based recommendation to help guide
treatment decisions. Looking at the four most common
modalities used to treat anterior epistaxis in the ED
from this study, the use of silver nitrate appears to be an
effective management option taking into account the
time and resources used for any other modality necessi-
tating a patient to return to the ED. This suggests that if
the anterior site of bleeding is identifiable, it is likely
amenable to chemical cautery, silver nitrate be the first
line treatment. However, due to limitations of the study,
and that there was no grading system to identify epi-
staxis severity, a recommendation of silver nitrate
cautery for all occurrences of anterior epistaxis can-
not be given at this time. Further study is needed to
determine the most efficacious treatment modality
based on epistaxis severity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SK conceived the study, and obtained ethics approval. SK supervised the
conduct of the trial and data collection. EN and AL undertook collecting
patient data, and management of the. EN, AL and WP provided statistical advice
on study design and helped analyze the data. EN drafted the manuscript, and all
authors contributed substantially to its revision. SK takes responsibility for the
paper as a whole. All authors read and approved the final manuscript.
Author details
1University of Ottawa, Ottawa, ON, Canada. 2Department of Otolaryngology -
Head and Neck Surgery, University of Ottawa, Ontario, Canada. 3Ottawa
Hospital Research Institute (OHRI), Ottawa, ON, Canada.
Received: 18 December 2015 Accepted: 4 April 2016
References
1. Pallin DJ, Chng YM, McKay MP, Emond JA, Pelletier AJ, Camargo Jr CA.
Epidemiology of epistaxis in US emergency departments, 1992 to 2001. Ann
Emerg Med. 2005;46:77–81.
2. Viehweg TL, Roberson JB, Hudson JW. Epistaxis: diagnosis and treatment.
J Oral Maxillofac Surg. 2006;64:511–8.
3. Abdelkader M, Leong SC, White PS. Endoscopic control of the sphenopalatine
artery for epistaxis: long-term results. J Laryngol Otol. 2007;121:759–62.
4. Bachelet JT, Bourlet J, Gleizal A. Hemostatic absorbable gel matrix for severe
post-traumatic epistaxis. Rev stomatol Chir Maxillofac Chir Orale. 2013;114:
310–4.
5. Badran K, Malik TH, Belloso A, Timms MS. Randomized controlled trial
comparing Merocel and RapidRhino packing in the management of
anterior epistaxis. Clin Otolaryngol. 2005;30:333–7.
6. Biggs TC, Baruah P, Mainwaring J, Harries PG, Salib RJ. Treatment
algorithm for oral anticoagulant and antiplatelet therapy in epistaxis
patients. J Laryngol Otol. 2013;127:483–8.
7. Killick N, Malik V, Nirmal Kumar B. Nasal packing for epistaxis: an evidence-
based review. Br J Hosp Med (London, England: 2005). 2014;75:143–4.
8. Kucik CJ, Clenney T. Management of epistaxis. Am Fam Physician. 2005;
71:305–11.
9. Morgan DJ, Kellerman R. Epistaxis: evaluation and treatment. Prim Care.
2014;41:63–73.
10. Toner JG, Walby AP. Comparison of electro and chemical cautery in the
treatment of anterior epistaxis. J Laryngol Otol. 1990;104:617–8.
11. Kilty SJ, Al-Hajry M, Al-Mutairi D, et al. Prospective clinical trial of
gelatin-thrombin matrix as first line treatment of posterior epistaxis.
Laryngoscope. 2014;124:38–42.
12. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a
novel matrix hemostatic sealant in patients with acute anterior epistaxis.
Laryngoscope. 2005;115:899–902.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Newton et al. Journal of Otolaryngology - Head and Neck Surgery  (2016) 45:24 Page 5 of 5
